Molecular Biology

N⁶-methyladenosine (m⁶A) is the most abundant internal modification in mRNA and is regulated primarily by the balance between the METTL3 methylase complex and two demethylases, FTO (fat mass and obesity-associated protein) and ALKBH5 (α-ketoglutarate-dependent dioxygenase alkB homolog). Reflecting this prevalence, m⁶A participates in virtually every step of RNA metabolism, influencing a wide range of physiological and pathological processes. The first step in studying m⁶A is genome-wide mapping, typically performed by m⁶A-seq, which sequences RNA fragments immunoprecipitated with an m⁶A-specific antibody. This is followed by identification of RRACH motifs (R = A or G; H = A, C, or U) within these sequences, with m⁶A being located at the third nucleotide. The second step involves mutating the putative m⁶A sites to establish a causal link between the modification and downstream biological effects. Since the mapping step has been covered in several detailed protocols, this article focuses on the second step—mutagenesis of RRACH motifs and subsequent functional analysis of the mutations by ectopic expression. The 3′ untranslated region (UTR) of the mouse Runx2 gene is used as an example. The mutant and wild-type sequences are inserted into a luciferase reporter vector and transfected into 293FT cells to evaluate how loss of m⁶A affects luciferase protein levels. The same reporter plasmids are also used in an RNA stability assay with a transcription inhibitor. Although site-specific demethylation of endogenous mRNA would be preferable, it remains technically challenging despite many attempts. Thus, ectopic expression of the mutated target gene remains a widely used and practical alternative.

N⁶-methyladenosine (m6A) is an abundant internal mRNA modification with roles in regulating cellular and organismal physiology, including development, differentiation, and disease. The deposition of m6A is highly regulated, with various m6A levels across different environmental conditions, cellular states, and cell types. Available methods for measuring bulk m6A levels are often time-consuming, have low throughput, and/or require specialized instrumentation or data analyses. Here, we present a detailed protocol for measuring bulk m6A levels in purified poly(A) RNA samples with m6A-ELISA using a standard-based approach. Critical steps of the protocol are highlighted and optimized, including poly(A) RNA quality controls and antibody specificity testing. The protocol is fast, scalable, adaptable, and cost-effective. It does not require specialized instrumentation, training, or skills in data analysis. We have successfully tested this protocol on mRNAs isolated from budding yeast and mouse cell lines.

A covalently closed loop structure provides circular RNA (circRNA) with more stability than conventional RNAs in linear form, making circRNA an emerging tool in RNA therapeutics. The qualification and quantification of circRNA after production is critical for its design and effectiveness assessments, particularly when the following applications could be affected by byproduct RNAs. Despite PCR-based methods effectively detecting low-abundance circRNA, they are unsuitable for assessing uncircularized RNA in a mass production fraction to maintain quality control. Here, we present a straightforward protocol for evaluating uncircularized byproduct RNAs from circRNA production. This method enrolls the template-independent RNA polymerase activity to add adenine tails (polyA) to the 3' ends of a linear RNA, making it easy to distinguish trace byproducts or uncircularized RNA from a pool of mass circRNA products. With conventional linear RNA and RNase R-treated circRNA as the positive and negative controls, the purity of a circRNA preparation could be readily resolved. Regardless of circRNA production strategies, this protocol provides a reliable and practical way to ensure the consistent quality of homemade circRNAs or to recheck circRNA quality from commercial manufacturing.